Skip to content
Open access

Aggregation, Propagation and Pathological Implications of α-synuclein Amyloid Fibrils in Parkinson’s Disease

TL;DR

It is shown that α-synuclein fibrils are more structurally heterogenous than previously believed and that they may continue to remodel their architecture over the course of PD, and fibril assembly pathways and resulting fibril structure are highlighted as critical targets for future therapeutic strategies.

Abstract

Parkinson’s disease (PD) is a severe, progressive neurodegenerative disorder characterized by aggregation of the protein α-synuclein into amyloid fibrils, leading to the formation of Lewy bodies and Lewy neurites and degeneration of dopaminergic neurons in the substantia nigra. Although α-synuclein aggregation is a defining feature of PD, fundamental questions remain regarding how fibrils form, how aggregation pathways encode distinct structural polymorphs, and how these polymorphs influence prion-like propagation and neurodegeneration. This knowledge gap continues to challenge the development of effective therapeutics. This thesis addresses several of these knowledge gaps by investigating the aggregation and prion-like propagation of α-synuclein amyloid fibrils using wild-type and familial PD-associated variants. First, to understand how assembly conditions shape α-synuclein fibril formation and structure, I examined the effects of monovalent cations. I show that the physiologically abundant cations Na+ and K+, although often treated as interchangeable, produce distinct effects on aggregation kinetics and fibril morphology, demonstrating that changes in ionic conditions can reshape α-synuclein fibril assembly pathways. I next investigated consequences of fibril fragmentation, a mechanism that rarely occurs in vitro but can be significant in vivo, showing that early-onset PD variants underwent pronounced structural evolution following fragmentation, reflected in altered Thioflavin-T binding. This shows that α-synuclein fibrils are more structurally heterogenous than previously believed and that they may continue to remodel their architecture over the course of PD. To resolve such heterogeneity, I established a Thioflavin-T fluorescence-lifetime spectroscopy-based methodology for phenotyping of α-synuclein polymorphs. Cross-seeding experiments revealed variant-specific structural trajectories, including faithful templating, monomer-driven restructuring, and emergence of de novo polymorphs, highlighting the vast structural landscape accessible to α-synuclein fibrils. Finally, I investigated whether these in vitro traits influenced prion-like propagation in cells, showing that α-synuclein variants differed markedly in uptake efficiency, induction of endosomal enlargement, and ability to seed endogenous α-synuclein aggregation. These cellular outcomes aligned with the structural and kinetic behaviors observed in vitro, demonstrating that propagation efficiency is strongly shaped by intrinsic fibril properties.Altogether, this work advances the mechanistic understanding of α-synuclein aggregation and propagation in PD and highlights fibril assembly pathways and resulting fibril structure as critical targets for future therapeutic strategies.

Read PDF

Similar papers

Open access Sep 2026

Aβ42-Driven α-synuclein Fibril Polymorphism and Distinct Intracellular Aggregation

Heterotypic interactions with Aβ42 reshape α-syn aggregation pathways and fibril conformations, generating structurally distinct α-syn fibril populations with different neuronal seeding activities, which provide a molecular framework for understanding how cross-talk between amyloidogenic proteins may contribute to stru...

Purnopama Saha, Teshani Liyanaarachchige, Anika Alim et al. · 0 citations
Open access Aug 2026

Multiple system atrophy-derived α-synuclein fibrils are more potent and display oligodendrocyte cell tropism compared to Parkinson's disease-derived fibrils.

Interestingly, amplified material from MSA brains induced significantly more oligodendroglial pSyn aggregates than amplified material from PD brains, and mice injected with the fibril polymorph, showed mild changes in microglial reactivity.

Anne-Line Strange Laursen, K. Willén, Alexis Fenyi et al. · 0 citations
Open access Aug 2026

Neuronal AIMP2–α-synuclein synergy drives endogenous tau and amyloid-β pathologies and neurodegeneration in a mechanistic model of Lewy body dementia

A genetically controlled in vivo model of LBD-like mixed proteinopathy recapitulating αSyn aggregation, tau hyperphosphorylation, Aβ accumulation, neurodegeneration, and behavioral decline is established and supports a mechanistic link between AIMP2-enhanced αSyn toxicity and secondary proteinopathies.

Doeun Kim, Hee-Tae Kim, Ji Hun Kim et al. · 0 citations
Review Open access Sep 2026

Targeting protein aggregate co-pathologies in neurodegeneration: a viable therapeutic strategy?

Many neurodegenerative diseases are characterized by pathological protein aggregation in the brain. Alzheimer’s disease displays amyloid-β and tau inclusions in the form of amyloid-β plaques and tau neurofibrillary tangles. Synucleinopathies comprise Parkinson’s disease and Dementia with Lewy bodies, which are classifi...

Silas A. Buck, Sidharth S. Madhavan, Laurie H. Sanders · 0 citations
Review 2026

Glial control of extracellular α-synuclein propagation in LRRK2 Parkinson's disease.

This review synthesises current evidence on how mutations in Leucine-Rich Repeat Kinase 2 (LRRK2), the most common genetic cause of familial PD, fundamentally corrupt glial handling of extracellular α-synuclein and evaluates emerging therapeutic strategies targeting LRRK2 kinase activity, NLRP3 inflammasome activation,...

Indrani Datta, Dibyam Debasish Sahu · 0 citations
Open access Aug 2026

Targeted degradation of alpha-synuclein impedes PFF-induced aggregation

The Affinity-directed PROtein Missile system is employed and targeted degradation of α-synuclein impedes the pre-formed fibril (PFF)-induced aggregation of α-synuclein in primary neurons derived from rats expressing human α-synuclein.

Bill Carton, Géraldine Gelders, Gajanan Sathe et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.